Actively Recruiting
A Prospective, Observational Study to Explore the Efficacy and Safety of Salvage Therapy With Glofitamab in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Led by The First Affiliated Hospital of Soochow University · Updated on 2024-07-11
50
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and safety of glofitamab combined with salvage therapy in real-world settings among Chinese adults diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma. This observational study aims to gather data on how well this combination works and its safety profile in everyday clinical practice. Participants in this study will receive glofitamab as part of their salvage therapy, administered by their physicians according to local clinical guidelines and practice. The study observes patients during their treatment without assigning specific interventions, reflecting real-world use of glofitamab in managing their lymphoma. During the study, researchers will monitor patient responses using criteria for malignant lymphoma to assess the best complete response rate up to about nine months from baseline. Additional outcomes include overall response rate, duration of response, progression-free survival, event-free survival, overall survival, and time to next treatment, with follow-up extending up to approximately 24 months. Safety and efficacy data are collected to better understand treatment impact in this patient population.
CONDITIONS
Brief Title
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with B-cell non-Hodgkin lymphoma
- Relapsed or refractory to previous treatment
- Planned to be treated with glofitamab
You will not qualify if you...
- Currently participating in or planning to participate in any interventional clinical trial
- Any other reason the investigator considers the participant unsuitable for the study based on their opinion or assessment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 9 months
Participants receive glofitamab in combination with salvage therapy as part of routine clinical care, administered at the discretion of their physician.
Duration - Up to approximately 24 months
Participants are monitored for efficacy and safety outcomes including response rates, survival, and duration of response after treatment ends.
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
H
Haiwen Huang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here